3 No-Brainer Dividend Stocks to Buy Right Now

AbbVie (ABBV) is presented as a Dividend King with a forward dividend yield of 3.1% and a forward P/E under 16 versus the S&P 500's 22.2 and the healthcare sector's 18.5, signaling an attractively valued pharma in growth mode post-patent cliff. Enbridge (ENB) offers a 6.1% forward yield, 30 consecutive years of increases, lower volatility with higher long-term total shareholder returns than peers, and projects ~$50 billion of growth opportunities through 2030 (about half in gas transmission). Realty Income (O) yields 5.5%, has raised its dividend for 112 consecutive quarters, pays monthly, and owns 15,542 properties leased to 1,647 clients across 92 industries, underpinning a safety-plus-growth income case for investors.

Analysis

Market structure: High-yield, defensive cash-flow names (ABBV, ENB, O) directly benefit as income-seeking flows rotate from low-yield cash/bonds into equities with stable distributions; ABBV’s forward P/E <16 and 3.1% yield trade like late-cycle defensive growth, ENB’s 6.1% yield and $50B growth through 2030 position it as a quasi-utility growth play, and O’s monthly 5.5% supports retail investor demand. Losers: interest-rate sensitive, low-cash-flow cyclicals and low-quality REITs that compete for capital will underperform.

Risk assessment: Tail risks include ABBV patent or regulatory setbacks (loss of >$1B annual cash flow could cut dividend trajectory), a sharp commodity demand shock reducing ENB throughput volumes >10% YoY, or a REIT occupancy collapse >200bp NOI compression for O. Immediate risks (days–weeks) center on earnings/FDA headlines; medium-term (3–12 months) around macro rates and energy demand; long-term (years) execution on ENB’s $50B backlog and ABBV new-drug commercialization.

Trade implications: Direct plays favor buy-and-hold income positions scaled into weakness: accumulate ENB and O on any 8–12% pullback; add ABBV when dividend yield gaps >40bp vs S&P healthcare. Use covered-call overlays on ENB/O to boost yield and buy protective puts around major catalysts (ABBV earnings/FDA dates). Pair trades: long O vs short mall-centric REITs to capture spread compression as high-quality retail landlords re-rate.

Contrarian angles: Consensus underestimates regulatory or demand risk — ABBV’s multiple compresses quickly on a single pipeline failure or trial loss, and ENB’s long-cycle capex could disappoint if natural gas-to-power demand growth stalls post-2028. Market may be underpricing optionality in ABBV’s pipeline replacement drugs; selectively buy LEAP calls as asymmetric upside if you have a multi-year horizon, but size positions given binary outcomes.

Key Decisions for Investors

• Establish a 2–3% long position in ABBV (NYSE: ABBV) over next 4–8 weeks; add on any >8% share-price pullback or if forward dividend yield rises above 3.6%. Target 12–18 month price appreciation to close P/E gap to sector (~18.5) and collect dividends; place a 15% stop-loss beneath entry to limit binary trial/regulatory risk.
• Build a 3–4% buy-and-hold allocation to Enbridge (NYSE: ENB) phased over Q1–Q4 2026; dollar-cost average and increase allocation on any 10%+ selloff. Overlay 6–9 month covered calls to boost yield by ~200–300bp and purchase 18–24 month out-of-the-money puts (e.g., 80–85% strike) as protection against a >15% drawdown.
• Take a 2–3% long position in Realty Income (NYSE: O) to capture monthly cash flow; if O’s dividend yield widens >50bp versus its 5-year average, add incrementally. Implement pair trade: long O vs short 0.5–1% of capital in a mall-centric REIT such as SPG to exploit credit/quality spread, rebalancing quarterly.
• For tactical upside on binary outcomes, buy ABBV Jan 2028 LEAP calls (delta ~0.35–0.45) sized no more than 0.5–1% of portfolio as an asymmetric bet on successful new-product commercialization; liquidate or hedge if trial/regulatory news increases implied volatility >40%.